ANHYDRON
LOE ApproachingNDAORALTABLET
Approved
Aug 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANHYDRON is an oral tablet small molecule approved by Eli Lilly in 1963 for an unknown indication. The mechanism of action and pharmacologic class are not publicly documented in available data.
LOE Approaching
Late-stage lifecycle product with minimal current revenue visibility and limited commercial team expansion opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANHYDRON represents a legacy product with minimal active job creation and declining commercial relevance. Career opportunities are limited to managing mature product decline, compliance, or supply optimization rather than growth initiatives.
Product Manager (Legacy)Regulatory Affairs Specialist
Worked on ANHYDRON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.